RE:RE:RE:RE:RE:Ru(II) Complexes Bearing O, O-Chelated Ligands Induced Apopt 1. Introduction
As a new class of nonplatinum metal complexes, ruthenium-based compounds possess valuable photophysical and photochemical properties and high structural diversity, which provide more direction for designing new ruthenium anticancer drugs [1, 2]. More importantly, ruthenium-based complexes often show better tumor cell selectivity than platinum metal complexes, in addition to low toxicity to normal cells and multiple anticancer mechanisms, thus making them attractive chemotherapeutic agents [3, 4]. So far, there are four ruthenium complexes with different ligands, that is, [ImH][trans-RuCl4(DMSO)(Im)] (NAMI-A) [5, 6], [IndH][trans-RuCl4(Ind)2] (KP1019) [7], KP133910 [8], and the Ru(II)-based photosensitizer, TLD1433 [9, 10], have progressed to different stages in clinical trials. In the review paper, Chen et al. pointed out that the selection of ligands plays a key role in the antitumor cell selectivity, targeting, antitumor activity, and mechanism of ruthenium compounds [3].
Citation # 10
S. Monro, K. L. Coln, H. Yin et al., “Transition metal complexes and photodynamic therapy from a tumor-centered approach: challenges, opportunities, and highlights from the development of TLD1433,” Chemical Reviews, vol. 119, no. 2, pp. 797–828, 2019.View at: Publisher Site | Google Scholar